Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M, et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1323-30.
Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58(1):26-35.
Dillon CF, Rasch EK, Gu Q, Hirsch R., Prevalence of knee osteoarthritis in the United States: arthritis data from the Third National Health and Nutrition Examination Survey 1991-1994. J Rheumatol. 2006;33(11):2271-9.
Jonsson H, Olafsdottir S, Sigurdardottir S, Aspelund T, Eiriksdottir G, Sigurdsson S, et al. Incidence and prevalence of total joint replacements due to osteoarthritis in the elderly: risk factors and factors associated with late life prevalence in the AGES-Reykjavik Study. BMC Musculoskelet Disord. 2016;17:14. doi:10.1186/s12891-016-0864-7.
Altman R, Lim S, Steen RG, Dasa V., Hyaluronic acid injections are associated with delay of total knee replacement surgery in patients with knee osteoarthritis: evidence from a large US health claims database. PLoS One. 2015;10(12):e0145776. doi:10.1371/journal.pone.0145776.
Altman R, Fredericson M, Bhattacharyya SK, Bisson B, Abbott T, Yadalam S, et al. Association between hyaluronic acid injections and time-to-total knee replacement surgery. J Knee Surg. 2016;29(7):564-70.
Wobig M, Dickhut A, Maier R, Vetter G., Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther. 1998;20(3):410-23.
Altman RD, Rosen JE, Bloch DA, Hatoum HT, Korner P., A double-blind, randomized, saline-controlled study of the efficacy and safety of EUFLEXXA for treatment of painful osteoarthritis of the knee, with an open-label safety extension (the FLEXX trial). Semin Arthritis Rheum. 2009;39(1):1-9.
Navarro-Sarabia F, Coronel P, Collantes E, Navarro FJ, de la Serna AR, Naranjo A, et al; AMELIA Study Group. A 40-month multicentre, randomised placebo-controlled study to assess the efficacy and carry-over effect of repeated intra-articular injections of hyaluronic acid in knee osteoarthritis: the AMELIA project. Ann Rheum Dis. 2011;70(11):1957-62.
Chevalier X, Jerosch J, Goupille P, van Dijk N, Luyten FP, Scott DL, et al. Single, intra-articular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo controlled trial. Ann Rheum Dis. 2010;69(1):113-9. doi:10.1136/ard.2008.094623.
Bannuru RR, Schmid CH, Kent DM, Vaysbrot EE, Wong JB, McAlindon TE., Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med. 2015;162(1):46-54. doi:10.7326/M14-1231.
Campbell KA, Erickson BJ, Saltzman BM, Mascarenhas R, Bach BR, Jr Cole BJ, et al. Is local viscosupplementation injection clinically superior to other therapies in the treatment of osteoarthritis of the knee: a systematic review of overlapping meta-analyses. Arthroscopy. 2015;31(10):2036-45.e14. doi:10.1016/j.arthro.2015.03.030.
Posnett J, Dixit S, Oppenheimer B, Kili S, Mehin N., Patient preference and willingness to pay for knee osteoarthritis treatments. Patient Prefer Adherence. 2015;9:733-44. doi:10.2147/PPA.S84251.
Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008;16(2):137-62.
Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, et al; Standing Committee for International Clinical Studies Including Therapeutic Trials ESCISIT. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62(12):1145-55.
Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on osteoarthritis guidelines. Arthritis Rheum. 2000;43(9):1905-15.
Jevsevar DS, Brown GA, Jones DL, Matzkin EG, Manner PA, Mooar P, et al; American Academy of Orthopedic Surgeons. The American Academy of Orthopaedic Surgeons evidence-based guideline on: treatment of osteoarthritis of the knee, 2nd edition. J Bone Joint Surg Am. 2013;95(20):1885-6.
Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012;64(4):465-74.
McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014;22(3):363-88.
Masuko K, Murata M, Yudoh K, Kato T, Nakamura H., Anti-inflammatory effects of hyaluronan in arthritis therapy: not just for viscosity. Int J Gen Med. 2009;2:77-81.
Gomis A, Miralles A, Schmidt RF, Belmonte C., Intra-articular injections of hyaluronan solutions of different elastoviscosity reduce nociceptive nerve activity in a model of osteoarthritic knee joint of the guinea pig. Osteoarthritis Cartilage. 2009;17(6):798-804.
Hirota W., Intra-articular injection of hyaluronic acid reduces total amounts of leukotriene C4, 6-keto-prostaglandin F1α, prostaglandin F2α and interleukin-1β in synovial fluid of patients with internal derangement in disorders of the temporomandibular joint. Br J Oral Maxillofac Surg. 1998;36(1):35-8.
Chang CC, Hsieh MS, Liao ST, Chen YH, Huang PT, Lin YF, et al. Hyaluronan regulates PPARγ and inflammatory responses in IL-1β-stimulated human chondrosarcoma cells, a model for osteoarthritis. Carbohydr Polym. 2012;90(2):1168-75.
Miki Y, Teramura T, Tomiyama T, Onodera Y, Matsuoka T, Fukuda K, et al. Hyaluronan reversed proteoglycan synthesis inhibited by mechanical stress: possible involvement of antioxidant effect. Inflamm Res. 2010;59(6):471-7.
Peng H, Zhou JL, Liu SQ, Hu QJ, Ming JH, Qiu B., Hyaluronic acid inhibits nitric oxide-induced apoptosis and dedifferentiation of articular chondrocytes in vitro. Inflamm Res. 2010;59(7):519-30.
Akmal M, Singh A, Anand A, Kesani A, Aslam N, Goodship A, et al. The effects of hyaluronic acid on articular chondrocytes. J Bone Joint Surg Br. 2005;87(8):1143-9.
Nicholls MA, Fierlinger A, Niazi F, Bhandari M., The disease-modifying effects of hyaluronan in the osteoarthritic disease state. Clin Med Insights Arthritis Musculoskelet Disord. Epub August 11, 2017. doi:10.1177/1179544117723611.
Henrotin Y, Chevalier X, Deberg M, Balblanc JC, Richette P, Mulleman D, et al; Osteoarthritis Group of French Society of Rheumatology. Early decrease of serum biomarkers of type II collagen degradation (Coll2-1) and joint inflammation (Coll2-1 NO2) by hyaluronic acid intra-articular injections in patients with knee osteoarthritis: a research study part of the Biovisco study. J Orthop Res. 2013;31(6):901-7.
Henrotin Y, Berenbaum F, Chevalier X, Marty M, Richette P, Rannou F., Reduction of the serum levels of a specific biomarker of cartilage degradation (Coll2-1) by hyaluronic acid (KARTILAGE® CROSS) compared to placebo in painful knee osteoarthritis patients: the EPIKART study, a pilot prospective comparative randomized double blind trial. BMC Musculoskelet Disord. 2017;26;18(1):222.
McAlindon TE, Driban JB, Henrotin Y, Hunter DJ, Jiang GL, Skou ST, et al. OARSI clinical trials recommendations: design, conduct, and reporting of clinical trials for knee osteoarthritis. Osteoarthritis Cartilage. 2015;23(5):747-60.
Henrotin Y, Raman R, Richette P, Bard H, Jerosch J, Conrozier T, et al. Consensus statement on viscosupplementation with hyaluronic acid for the management of osteoarthritis. Semin Arthritis Rheum. 2015;45(2):140-9.
Raman R, Henrotin Y, Chevalier X, Migliore A, Jerosch J, Monfort J, et al. Decision algorithms for the re-treatment with viscosupplementation in patients suffering from knee osteoarthritis. Recommendations from the EUROpean VIScosupplementation COnsensus group (EUROVISCO). Cartilage. Epub February 1, 2017. doi:10.1177/1947603517693043.
Eymard F, Chevalier X, Conrozier T., Obesity and radiological severity are associated with viscosupplementation failure in patients with knee osteoarthritis. J Orthop Res. 2017;35(10):2269-74. doi:10.1002/jor.23529.
Guermazi A, Roemer FW, Haugen IK, Crema MD, Hayashi D., MRI-based semiquantitative scoring of joint pathology in osteoarthritis. Nat Rev Rheumatol. 2013;9(4):236-51.
Felson D, Niu J, Guermazi A, Sack B, Aliabadi P., Defining radiographic incidence and progression of knee osteoarthritis: suggested modifications of the Kellgren and Lawrence scale. Ann Rheum Dis. 2011;70(11):1884-6.
Altman RD, Gold GE., Radiographic atlas for osteoarthritis of the hand, hip and knee. Osteoarthritis Cartilage. 2007;15(Suppl A):A1-56.
Brandt KD, Mazzuca SA, Conrozier T, Dacre JE, Peterfy CG, Provvedini D, et al. Which is the best radiographic protocol for a clinical trial of a structure modifying drug in patients with knee osteoarthritis? J Rheumatol. 2002;29(6):1308-20.
Conrozier T, Brandt K, Piperno M, Mathieu P, Merle-Vincent F, Vignon E., Reproducibility and sensitivity to change of a new method of computer measurement of joint space width in hip osteoarthritis. Performance of three radiographic views obtained at a 3-year interval. Osteoarthritis Cartilage. 2009;17(7):864-70.
Hayashi D, Roemer FW, Guermazi A., Imaging for osteoarthritis. Ann Phys Rehabil Med. 2016;59(3):161-9.
Boesen M, Ellegaard K, Henriksen M, Gudbergsen H, Hansen P, Bliddal H, et al. Osteoarthritis year in review 2016: imaging. Osteoarthritis Cartilage. 2017;25(2):216-26.
Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW., Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988; 15(12):1833-40.
Roos EM, Roos HP, Lohmander LS, Ekdahl C, Beynnon BD., Knee injury and osteoarthritis outcome score (KOOS)—development of a self-administered outcome measure. J Orthop Sports Phys Ther. 1998;28(2):88-96.
Pham T, Van Der Heijde D, Lassere M, Altman RD, Anderson JJ, Bellamy N, et al; OMERACT-OARSI. Outcome variables for osteoarthritis clinical trials: the OMERACT-OARSI set of responder criteria. J Rheumatol. 2003;30(7):1648-54.
Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, et al. Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state. Ann Rheum Dis. 2005;64(1):34-7.
Henrotin Y, Sanchez C, Bay-Jensen AC, Mobasheri A., Osteoarthritis biomarkers derived from cartilage extracellular matrix: current status and future perspectives. Ann Phys Rehabil Med. 2016;59(3):145-8.
Conaghan PG, Hunter DJ, Maillefert JF, Reichmann WM, Losina E., Summary and recommendations of the OARSI FDA osteoarthritis Assessment of Structural Change Working Group. Osteoarthritis Cartilage. 2011;19(5):606-10.
Hunter DJ, Altman RD, Cicuttini F, Crema MD, Duryea J, Eckstein F, et al. OARSI clinical trials recommendations: knee imaging in clinical trials in osteoarthritis. Osteoarthritis Cartilage. 2015;23(5):698-715.
Chrysochou C1, Buckley DL, Dark P, Cowie A, Kalra PA. Gadolinium-enhanced magnetic resonance imaging for renovascular disease and nephrogenic systemic fibrosis: critical review of the literature and UK experience. J Magn Reson Imaging. 2009;29(4):887-94.
Kraus VB, Burnett B, Coindreau J, Cottrell S, Eyre D, Gendreau M, et al; OARSI FDA Osteoarthritis Biomarkers Working Group. Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthritis Cartilage. 2011;19(5):515-42.
